Showing 1407 results
-
Story /The fast-spreading virus can take multiple routes into developing human nerve cells.
-
Press release /If approved, Xolair® (omalizumab) will provide patients who have severe chronic rhinosinusitis with nasal polyps, not adequately controlled by intranasal corticosteroids, with the first anti-…
-
Press release /Approved based on a first-line Phase III trial that met its primary endpoint of progression-free survival (PFS) at interim analysis due to superior efficacy compared to letrozole alone[1] …
-
Media Library / -
Media Library / -
Media Library / -
Press release /Xolair® (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU)[1], is the only therapy recommended by the guideline for patients unresponsive to…
-
Press release /Significant improvement in PFS seen with Arzerra plus chlorambucil in previously untreated patients with CLL for whom fludarabine-based therapy was inappropriate Chronic lymphocytic…
-
Press release /New analyses show Novartis' Entresto(TM) reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless of prior heart…
-
Press release /The study published in ‘Neurology and Therapy’ also shows the fatal outcomes and hospitalization rates due to COVID-19 in those treated with Kesimpta were in line with the rates in the general MS…